Tamoxifen

Tamoxifen is the backbone of PCT for most users because it is well-studied, well-tolerated by most people, and directly addresses the HPTA restart goal. It is also the preferred on-cycle tool for breast tissue protection in users who want targeted gynecomastia prevention without systemic estrogen crash.

Its 5–7 day half-life means blood levels build and maintain easily on once-daily dosing.

Use case: Most often used for PCT or early gynecomastia control. It does not lower estrogen production.

Administration: Once-daily dosing works because of the long half-life.

Decision rule: Use it when receptor blockade is the goal. Use an AI only when aromatization itself is the problem.

Stop or seek review if: vision changes, major mood issues, or clotting symptoms appear.

For PCT: LH and FSH begin rising within 1–2 weeks on tamoxifen. Testosterone recovery is typically measurable by weeks 3–4. Standard PCT length is 4–6 weeks, with labs drawn 4–6 weeks after stopping to confirm recovery.

For on-cycle gynecomastia prevention: protection is active within the first week of use.

Tamoxifen (Nolvadex) is a SERM, selective estrogen receptor modulator. It does not lower estrogen levels in the blood. It blocks [estrogen receptor] activation at specific tissues, primarily breast tissue. This distinction is critical: someone running tamoxifen during cycle has not reduced their estrogen; they have blocked estrogen from binding at the breast while estrogen continues to act elsewhere, including at tissues where estrogen has positive effects (bone, cardiovascular, libido, mood).

This makes tamoxifen the preferred tool for protecting against gynecomastia specifically, without the systemic estrogen suppression risks of aromatase inhibitors. Users who find they are sensitive to gynecomastia even at moderate estrogen levels often run low-dose tamoxifen during cycle rather than over-suppressing estrogen with an AI.

In PCT, tamoxifen’s mechanism works differently: by blocking the estrogen receptor at the hypothalamus and pituitary, it removes the estrogen feedback signal that suppresses LH and FSH output. With that brake removed, LH and FSH rise, stimulating testicular testosterone production. The HPTA begins to restart. This is the foundation of most PCT protocols.

Using tamoxifen to manage estrogenic side effects that are not breast-specific, like water retention, mood changes, or libido issues during cycle. These require estrogen control (an AI), not receptor blocking. Tamoxifen does not help them.

Choosing high PCT doses (40mg+) out of assumption that more is better. Standard starting dose of 20mg/day is sufficient for most users; 40mg is used in the first 1–2 weeks only if a stronger initial push is warranted.

Running tamoxifen long-term on TRT without a clear indication. Chronic SERM use has its own hormonal and tissue-level consequences.

Compared with Clomiphene, tamoxifen is usually better tolerated. Clomiphene produces stronger LH stimulation but more mood side effects (emotional lability, visual disturbances). For most users, tamoxifen alone is sufficient for PCT. Combining both is used for harder recovery cases but is not necessary as standard protocol.

Compared with Arimidex or Aromasin, tamoxifen answers a different question. AIs lower estrogen; tamoxifen blocks receptor activation. On-cycle, users choose between them based on whether they want to reduce circulating estrogen or just protect breast tissue while maintaining higher estrogen elsewhere.